Alpha 2.0
Login Register
» Articles » PMID: 9665302

Comparative in Vitro Activity of BAY 12-8039 and Five Other Antimicrobial Agents Against Anaerobic Bacteria

Overview
Journal Eur J Clin Microbiol Infect Dis
Publisher Springer
Specialties Infectious Diseases
Microbiology
Date 1998 Jul 17
PMID 9665302
Citations 13
Authors
C Edlund
S Sabouri
C E Nord
Affiliations
Soon will be listed here.
Abstract

The in vitro activity of BAY 12-8039 against 360 anaerobic clinical isolates was determined by the agar dilution method and compared to that of five other antimicrobial agents. BAY 12-8039 and imipenem were the most active agents tested. The following MIC90 values were determined for BAY 12-8039: Peptostreptococcus spp. (50 isolates), 1 mg/l; Propionibacterium acnes (30 isolates). 0.25 mg/l; Clostridium perfringens (30 isolates), 0.5 mg/l; Clostridium difficile (50 isolates), 2 mg/l; Bacteroides fragilis (50 isolates), 1 mg/l; non-fragilis Bacteroides, Porphyromonas, and Prevotella spp. (100 isolates), 2 mg/l; and Fusobacterium spp. (50 isolates), 0.25 mg/l. The results of the present study show that BAY 12-8039 may be useful in the treatment and prophylaxis of anaerobic infections.

Citing Articles

Doxycycline and Tigecycline: Two Friendly Drugs with a Low Association with Clostridium Difficile Infection.

Hung Y, Lee J, Lin H, Liu H, Wu Y, Tsai P Antibiotics (Basel). 2016; 4(2):216-29.

PMID: 27025622 PMC: 4790331. DOI: 10.3390/antibiotics4020216.

The potential for emerging therapeutic options for Clostridium difficile infection.

Mathur H, Rea M, Cotter P, Ross R, Hill C Gut Microbes. 2015; 5(6):696-710.

PMID: 25564777 PMC: 4615897. DOI: 10.4161/19490976.2014.983768.

Future novel therapeutic agents for Clostridium difficile infection.

Koo H, Garey K, DuPont H Expert Opin Investig Drugs. 2010; 19(7):825-36.

PMID: 20521993 PMC: 3159574. DOI: 10.1517/13543784.2010.495386.

Clostridium difficile infection: update on emerging antibiotic treatment options and antibiotic resistance.

Shah D, Dang M, Hasbun R, Koo H, Jiang Z, DuPont H Expert Rev Anti Infect Ther. 2010; 8(5):555-64.

PMID: 20455684 PMC: 3138198. DOI: 10.1586/eri.10.28.

Moxifloxacin in the treatment of skin and skin structure infections.

Guay D Ther Clin Risk Manag. 2008; 2(4):417-34.

PMID: 18360653 PMC: 1936362. DOI: 10.2147/tcrm.2006.2.4.417.

References
1.
Finegold S . Anaerobic infections in humans: an overview. Anaerobe. 1995; 1(1):3-9. DOI: 10.1016/s1075-9964(95)80340-8. View
2.
Woodcock J, Andrews J, Boswell F, Brenwald N, Wise R . In vitro activity of BAY 12-8039, a new fluoroquinolone. Antimicrob Agents Chemother. 1997; 41(1):101-6. PMC: 163668. DOI: 10.1128/AAC.41.1.101. View
3.
Aldridge K, Ashcraft D . Comparison of the in vitro activities of Bay 12-8039, a new quinolone, and other antimicrobials against clinically important anaerobes. Antimicrob Agents Chemother. 1997; 41(3):709-11. PMC: 163778. DOI: 10.1128/AAC.41.3.709. View
4.
Nord C . In vitro activity of quinolones and other antimicrobial agents against anaerobic bacteria. Clin Infect Dis. 1996; 23 Suppl 1:S15-8. DOI: 10.1093/clinids/23.supplement_1.s15. View
5.
Dalhoff A, Petersen U, Endermann R . In vitro activity of BAY 12-8039, a new 8-methoxyquinolone. Chemotherapy. 1996; 42(6):410-25. DOI: 10.1159/000239474. View